IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Confirmation No.: 2116
ROBERT *et al.*	Art Unit: 1644
Appl. No.: 10/529,221	Examiner: DIBRINO, Marianne N.
Filed: June 30, 2006	Atty. Docket: 1843.0200001/EJH/M-N
For: **Targeted CD1d Molecules**	

Reply to Requirement For Election of Species

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated March 24, 2010, requesting the election of a single species of: (i) a type of linking group as recited in claims 52 and 53; (ii) a CD1d-antibody fragment complex, wherein the antibody fragment is fused to one of either the CD1d molecule or the β2-microglobulin molecule; (iii) a CD1d-antibody fragment complex, wherein the antibody fragment is fused to the CD1d/β2-microglobulin molecule either directly or through a peptide bridge linker of from about 3 to about 30 amino acid residues; and (iv) a peptide bridge linker sequence (*i.e.*, SEQ ID NO: 1 or SEQ ID NO: 2), Applicants hereby elect to prosecute a CD1d complex wherein the **scFv molecule is fused to the CD1d molecule** through a **peptide bridge linker** (claim 52) with **an amino acid sequence of from 3 to about 30 amino acid residues** (claim 57) having the linker sequence of **SEQ ID NO: 2** (claim 59).

Additionally, Applicants wish to clarify that the Examiner's assumption that "[t]he elected species enunciated supra has specificity (at its amino terminus) for the Her2/neu antigen" is incorrect. *See* Office Action at page 2. Based on the April 1, 2010 telephone discussion with the Examiner regarding this assumption and the request

specified at page 2 in the Office Action for the Applicants to "elect whether the CD1d molecule of the complex is linked to the amino terminus or to the carboxyl terminus of the antibody fragment," Applicants hereby also elect to prosecute a method of attachment where the CD1d molecule is located N-terminal to the scFv molecule (represented by claim 55).

Claims 1-4, 8, 10, 11, 36, 37, 40, 41, 49-52, 54, 55, 57, and 59 read on such species. These elections are made without prejudice to or disclaimer of the other claims or inventions disclosed. These elections are made **without traverse**.

It is believed that extensions of time are not required, beyond those that may otherwise be provided for in accompanying documents. However, in the event that additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Elizabeth J. Haanes, Ph.D.
Attorney for Applicants
Registration No. 42,613

Date: April 9, 2010

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
1097501_1.DOC